15:25 ET IDPH IDEC Pharm drops on Zevalin reimbursement chatter (40.90 -3.34) Stock has seen heavy selling in the last hour due to Street talk that Medicare officials are seeking ways to reduce Zevalin's reimbursement rate; we're hearing that the officials would like to reduce the $22k reimbursement rate proposed in the Aug 7 draft regulation by about $5k-$7k, although we would like to emphasize that this is just a rumor at this point and can't be confirmed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.